AACR 2024 | PROs in advanced cisplatin-ineligible UC: first-line EV ± pembrolizumab

Jonathan Rosenberg, MD, Memorial Sloan Kettering Cancer Center in New York, NY, presents findings from Cohort K of the Phase Ib/II EV-103 trial (NCT03288545), assessing the impact of first-line enfortumab vedotin (EV) alone or with pembrolizumab on quality of life (QOL), functioning, and symptoms in patients with locally advanced/metastatic urothelial cancer (la/mUC) who were cisplatin-ineligible. In this phase Ib/II trial, patients were randomly assigned to EV plus pembrolizumab or EV monotherapy. Patient-reported outcomes (PROs) were assessed using the EORTC QLQ-C30 and BPI-SF. Results showed maintenance or improvement of QOL/functioning/symptoms with EV plus pembrolizumab, with clinically meaningful improvements in pain observed in both arms. These findings complement clinical outcomes of first-line EV plus pembrolizumab. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.